SB 200646A

Known as: SB-200646A, SKB-200646A 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2011
0119942011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The effects of combined administration of afobazole and 5-НТ2b/2c receptor antagonist SB-200646A on the content of monoamines and… (More)
Is this relevant?
2011
2011
Effects of separate and combined introduction of afobazole and SB-200646A (highly selective 5-HT2B/2C receptor antagonist) on the… (More)
Is this relevant?
2006
2006
This study examined the effect of the acute and chronic administration of the 5-HT(2B/2C) receptor antagonist N-(1-methyl-5… (More)
Is this relevant?
2000
2000
The NMDA receptor/nitric oxide (NO)/cyclic GMP pathway and its modulation by 5-hydroxytryptamine (5-HT) was studied in slices of… (More)
Is this relevant?
1999
1999
1. There has been considerable research in the field of schizophrenia over the past few years with emphasis on the discovery of… (More)
Is this relevant?
1998
1998
5-HT(2C) receptors are predominantly localised in the brain and their dysregulation may contribute to particular symptoms of… (More)
Is this relevant?
1997
1997
In a recent study, we reported the presence of neurones expressing 5-HT2B receptor protein in the medial amygdaloid nucleus of… (More)
Is this relevant?
1995
1995
SB 200646A is the first selective 5-HT2C/5-HT2B receptor antagonist and has previously been observed to have anxiolytic-like… (More)
  • table 1
  • table 2
Is this relevant?
1994
1994
1. SB 200646A, N-(1-methyl-5-indolyl)-N'-(3-pyridyl) urea hydrochloride, the first reported selective 5-HT2C/2B over 5-HT2A… (More)
Is this relevant?